These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 38770814)

  • 1. Lessons learnt from daily oral PrEP delivery to inform national planning for PrEP ring introduction for women in low-income and middle-income countries: a qualitative inquiry of international stakeholders.
    Heck CJ; Dam A; Yohannes K; Deacon J; Kripke K; Meyers K; Poku O; Obermeyer C; Wiant S; Quigee D; Larson M; Malati C; Sobieszczyk ME; Torres-Rueda S; Castor D
    BMJ Glob Health; 2024 May; 9(5):. PubMed ID: 38770814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparing for long-acting PrEP delivery: building on lessons from oral PrEP.
    Celum C; Grinsztejn B; Ngure K
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26103. PubMed ID: 37439077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Securing accelerated access to long-acting injectable cabotegravir for HIV prevention in low- and middle-income countries.
    Jenkins SY; Resar D; Panos Z; Staple A; Watkins M; Ripin D; Amole C
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26101. PubMed ID: 37439082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introducing the Dapivirine Vaginal Ring in Sub-Saharan Africa: What Can We Learn from Oral PrEP?
    Bhavaraju N; Shears K; Schwartz K; Mullick S; Jeckonia P; Murungu J; Persaud U; Vij A; Torjesen K
    Curr HIV/AIDS Rep; 2021 Dec; 18(6):508-517. PubMed ID: 34910276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention.
    Reidy M; Gardiner E; Pretorius C; Glaubius R; Torjesen K; Kripke K
    PLoS One; 2019; 14(6):e0218710. PubMed ID: 31242240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementation strategies for integrating pre-exposure prophylaxis for HIV prevention and family planning services for adolescent girls and young women in Kenya: a qualitative study.
    Roche SD; Barnabee G; Omollo V; Mogaka F; Odoyo J; Bukusi EA; Morton JF; Johnson R; Celum C; Baeten JM; O'Malley G
    BMC Health Serv Res; 2022 Mar; 22(1):422. PubMed ID: 35354456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation and resource needs for long-acting PrEP in low- and middle-income countries: a scoping review.
    Castor D; Heck CJ; Quigee D; Telrandhe NV; Kui K; Wu J; Glickson E; Yohannes K; Rueda ST; Bozzani F; Meyers K; Zucker J; Deacon J; Kripke K; Sobieszczyk ME; Terris-Prestholt F; Malati C; Obermeyer C; Dam A; Schwartz K; Forsythe S
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26110. PubMed ID: 37439063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study.
    Grinsztejn B; Torres TS; Hoagland B; Jalil EM; Moreira RI; O'Malley G; Shade SB; Benedetti MR; Moreira J; Simpson K; Pimenta MC; Veloso VG;
    JMIR Public Health Surveill; 2023 Apr; 9():e44961. PubMed ID: 37074775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shaping and coordinating the implementation science agenda for injectable cabotegravir for PrEP: the role of the Biomedical Prevention Implementation Collaborative (BioPIC).
    Warren M; Nyagah W; Verde Hashim C; Rodolph M; Schaefer R; Schmidt HA; Baggaley R
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26094. PubMed ID: 37439050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness.
    Glaubius R; Ding Y; Penrose KJ; Hood G; Engquist E; Mellors JW; Parikh UM; Abbas UL
    J Int AIDS Soc; 2019 May; 22(5):e25282. PubMed ID: 31074936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rethinking HIV prevention to prepare for oral PrEP implementation for young African women.
    Celum CL; Delany-Moretlwe S; McConnell M; van Rooyen H; Bekker LG; Kurth A; Bukusi E; Desmond C; Morton J; Baeten JM
    J Int AIDS Soc; 2015; 18(4 Suppl 3):20227. PubMed ID: 26198350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial.
    Nair G; Celum C; Szydlo D; Brown ER; Akello CA; Nakalega R; Macdonald P; Milan G; Palanee-Phillips T; Reddy K; Tahuringana E; Muhlanga F; Nakabiito C; Bekker LG; Siziba B; Hillier SL; Baeten JM; Garcia M; Johnson S; McClure T; Levy L; Livant E; Jacobson C; Soto-Torres L; van der Straten A; Hosek S; Rooney JF; Steytler J; Bunge K; Parikh U; Hendrix C; Anderson P; Ngure K;
    Lancet HIV; 2023 Dec; 10(12):e779-e789. PubMed ID: 37898146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementing Differentiated and Integrated HIV Prevention Services for Adolescent Girls and Young Women: Experiences From Oral PrEP Rollout in Primary Care Services in South Africa.
    Butler V; Kutywayo A; Martin CE; Pleaner M; Mojapele MV; Ncube S; Fipaza Z; Mundeta B; Mullick S
    J Adolesc Health; 2023 Dec; 73(6S):S58-S66. PubMed ID: 37953010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimising HIV pre-exposure prophylaxis and testing strategies in men who have sex with men in Australia, Thailand, and China: a modelling study and cost-effectiveness analysis.
    Zhao R; Fairley CK; Cook AR; Phanuphak N; He S; Tieosapjaroen W; Chow EPF; Phillips TR; Jin Tan RK; Wei Y; Shen M; Zhuang G; Ong JJ; Zhang L
    Lancet Glob Health; 2024 Feb; 12(2):e243-e256. PubMed ID: 38245115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review of the values and preferences regarding the use of injectable pre-exposure prophylaxis to prevent HIV acquisition.
    Lorenzetti L; Dinh N; van der Straten A; Fonner V; Ridgeway K; Rodolph M; Schaefer R; Schmidt HA; Baggaley R
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26107. PubMed ID: 37439057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery.
    Celum CL; Delany-Moretlwe S; Baeten JM; van der Straten A; Hosek S; Bukusi EA; McConnell M; Barnabas RV; Bekker LG
    J Int AIDS Soc; 2019 Jul; 22 Suppl 4(Suppl Suppl 4):e25298. PubMed ID: 31328444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating preexposure prophylaxis delivery in routine family planning clinics: A feasibility programmatic evaluation in Kenya.
    Mugwanya KK; Pintye J; Kinuthia J; Abuna F; Lagat H; Begnel ER; Dettinger JC; John-Stewart G; Baeten JM;
    PLoS Med; 2019 Sep; 16(9):e1002885. PubMed ID: 31479452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influences on willingness to use vaginal or oral HIV PrEP during pregnancy and breastfeeding in Africa: the multisite MAMMA study.
    van der Straten A; Ryan JH; Reddy K; Etima J; Taulo F; Mutero P; Taylor J; Piper J; Musara P;
    J Int AIDS Soc; 2020 Jun; 23(6):e25536. PubMed ID: 32524700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards a fair consideration of PrEP as part of combination HIV prevention in Latin America.
    Ravasi G; Grinsztejn B; Baruch R; Guanira JV; Luque R; Cáceres CF; Ghidinelli M
    J Int AIDS Soc; 2016; 19(7(Suppl 6)):21113. PubMed ID: 27760687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial implementation of PrEP in Zambia: health policy development and service delivery scale-up.
    Claassen CW; Mumba D; Njelesani M; Nyimbili D; Mwango LK; Mwitumwa M; Mubanga E; Mulenga LB; Chisenga T; Nichols BE; Hendrickson C; Chitembo L; Okuku J; O'Bra H
    BMJ Open; 2021 Jul; 11(7):e047017. PubMed ID: 34244265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.